Emerging Effects of Sevelamer in Chronic Kidney Disease

Publisher： Karger

E-ISSN： 1423-0143|37|1|24-32

ISSN： 1420-4096

Source： Kidney and Blood Pressure Research, Vol.37, Iss.1, 2013-03, pp. : 24-32

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adolescents and Emerging Adults with Chronic Kidney Disease: Their Unique Morbidities and Adherence Issues

By  

Blood Purification, Vol. 31, Iss. 1-3, 2011-01 ,pp. : 203-208

Karger

Access to resources Recommend Favorite

Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT)

By  

Nephron, Vol. 134, Iss. 4, 2016-07 ,pp. : 215-220

Karger

Access to resources Recommend Favorite

Uromodulin and Chronic Kidney Disease

By  

Kidney and Blood Pressure Research, Vol. 33, Iss. 5, 2010-10 ,pp. : 393-398

Karger

Access to resources Recommend Favorite

Aging and Chronic Kidney Disease

By  

Kidney and Blood Pressure Research, Vol. 38, Iss. 1, 2014-03 ,pp. : 109-120

Karger

Access to resources Recommend Favorite

Potential Deleterious Effects of Vasopressin in Chronic Kidney Disease and Particularly Autosomal Dominant Polycystic Kidney Disease

By  

Kidney and Blood Pressure Research, Vol. 34, Iss. 4, 2011-06 ,pp. : 235-244

Karger

Access to resources Recommend Favorite